Overview

Gastric cancer treatment increasingly relies on matching therapy to tumor biology. A 70-gene gastric panel that integrates targeted-therapy genes, chemotherapy-response markers, and microsatellite instability or mismatch-repair (MSI/MMR) status brings these dimensions into one report. This combination strategy helps clinicians weigh multiple options at once rather than testing each biomarker in isolation.

The MSI/MMR Dimension

Deficient mismatch repair and microsatellite instability mark tumors with high mutational loading, which can respond to immune checkpoint inhibitors regardless of PD-L1 status. Including MSI/MMR in the same panel as targeted and chemotherapy data means a single test can flag both immunotherapy eligibility and conventional sensitivities. This is particularly relevant in gastric cancer, where MSI-high disease represents a distinct therapeutic subset.

Targeted and Chemotherapy Arms Together

The targeted arm points to alterations with established or emerging drug associations, while the chemotherapy-response arm provides decision-support for cytotoxic regimens. Presenting both in one report lets the treating team combine a targeted option with an appropriately chosen backbone, or select chemotherapy when no strong driver is present. The combination avoids the delay of sequential single-marker tests.

Building a Combined Plan

In practice, the panel supports a layered decision: first check MSI/MMR for immunotherapy candidacy, then review targeted alterations for matched agents, and finally weigh chemotherapy-response signals for backbone selection. Because all results arrive together from one sample, the plan can be assembled without consuming additional tissue through repeated biopsies.

Coordination with PD-L1 assessment strengthens the strategy further. Although MSI/MMR can indicate immunotherapy benefit independently, pairing the panel with PD-L1 IHC gives a fuller immune profile from complementary sample types. Laboratories that deliver both the NGS report and the IHC score in a linked workflow reduce the administrative burden on busy gastric cancer clinics and keep the combined evidence in one comparable record that is easy to revisit at subsequent visits.

FAQ

Q: Why include MSI/MMR in a gastric panel? A: MSI-high or dMMR gastric tumors can respond to immune checkpoint inhibitors, so the marker defines a distinct treatable subset.

Q: Does MSI status replace PD-L1 testing? A: No. They capture different mechanisms; MSI-high can indicate immunotherapy benefit independent of PD-L1 expression.

Q: How do targeted and chemo arms work together? A: The targeted arm suggests matched agents while the chemo arm informs backbone choice, supporting a combined plan from one report.

Q: Does one sample cover all three dimensions? A: Yes. A single nucleic-acid extraction supports targeted, chemotherapy, and MSI/MMR reporting without extra tissue. This efficiency is valuable in gastric cancer, where tissue can be scarce after surgical or endoscopic resection and where repeated biopsies carry real patient burden.